A PLOS Blog yesterday authored by Hilda Bastian discusses several issues relating to peer review, including: Do attempts to mask the identity of authors affect acceptance or rejection of manuscripts, … Continue Reading Weighing Up Anonymity and Openness in Publication Peer Review
How long does a scientific paper need to be? Do length limits have a detrimental effect on scientific reporting?
A blog this week by the London School of Economics and Political Science questions the current policy of many journals to restrict manuscript word count. In principle, length limits should … Continue Reading How long does a scientific paper need to be? Do length limits have a detrimental effect on scientific reporting?
An article in the Danish Medical Journal this week discusses the importance of establishing rules for authorship in multicentre trials. These trials may involve up to hundreds of contributors, but … Continue Reading The importance of authorship contracts in multicentre trials (including access to free templates)
Heeding calls from the Institute of Medicine, WHO, and the Nordic Trial Alliance, The BMJ are extending their policy on requiring the sharing of individual patient data for trials of … Continue Reading The BMJ have extended their policy relating to sharing clinical trial data (@bmj_latest)
Evidence-informed recommendations to reduce dissemination bias in clinical research: conclusions from the OPEN project
The aims of the OPEN project (http://www.open-project.eu) are to assess the current evidence on publication bias and to describe current practices by various key groups involved in funding, conducting and … Continue Reading Evidence-informed recommendations to reduce dissemination bias in clinical research: conclusions from the OPEN project
A study from the Association of the British Pharmaceutical Industry (ABPI) published this week in the peer-review journal Current Medical Research and Opinion (CMRO) suggests that transparency amongst industry-sponsored clinical … Continue Reading New study suggests that transparency amongst industry-sponsored clinical trials is improving
A blog today in The BMJ provides further commentary on predatory journals. The blog provides a good overview of how to recognise predatory journals, and provides a variety of tips. … Continue Reading Predatory journals – a bad dream turning into a nightmare (BMJ Blog by @jocalynclark)
What can we do to increase trust in peer review? How can we encourage more researchers to take part in peer review? These were just some of the issues considered … Continue Reading Righting peer review: Are trust and incentives the key?
Transforming the subscription journals’ business model to facilitate the necessary large-scale transformation to open access
A Max Planck Digital Library Open Access Policy White Paper published this week makes a case for a large-scale transformation of the current corpus of scientific subscription journals to an … Continue Reading Transforming the subscription journals’ business model to facilitate the necessary large-scale transformation to open access
The AllTrials campaign calls for all past and present clinical trials to be registered and their full methods and summary results reported. At the recent Evidence Live congress, Sir Iain … Continue Reading Presentation on the #AllTrials campaign (to register and report findings from all clinical trials)
Revised guidelines relating to the development of medical publications to be published in the near future (GPP-3)
Most people involved in the development of medical publications – and particularly those from industry – are familiar with the Good Publication Practice (GPP)-2 guidelines, which were published in 2009. … Continue Reading Revised guidelines relating to the development of medical publications to be published in the near future (GPP-3)
In this short video from the ISMPP 2015 annual meeting, Daniel Shanahan (Associate Publisher at BioMed Central) discusses patient peer review and BioMed Central’s decision to include patients in the … Continue Reading Involvement of patients in the journal peer review process
An editorial in the Cochrane Library from the last week argues that clinical trial information from regulators should be included in systematic reviews of treatments. In 2014, the authors of … Continue Reading Should regulatory data from the EMA and the FDA be included in systematic reviews?
A new report, written by Nordic clinical trial experts, sets a high international standard for clinical trial transparency and sets out how to make it a reality. The report from … Continue Reading Nordic researchers want to lead the world in clinical trial transparency